19
1
49
2
8
1b
1d
18
34
7b
1d
2 29
1d
25
Alexis Ogdie, MD, MSCE
78
7b
Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
40
4
3
3
3
2
4
b
1f
40
3400 Spruce Street
18 5 White Building
52 Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
26
18 5 White Building
52 Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
2e
Office: 215-662-2454
32 Fax: 215-662-4500
24
f
32 Fax: 215-662-4500
24
13
Education:
21 7 BS c
30 University of Minnesota, 2002.
21 7 MD c
41 Georgetown University School of Medicine, 2006.
21 9 MSCE c
33 University of Pennsylvania, 2012.
c
3
3
3
3
92
Permanent link21 7 BS c
30 University of Minnesota, 2002.
21 7 MD c
41 Georgetown University School of Medicine, 2006.
21 9 MSCE c
33 University of Pennsylvania, 2012.
c
2 29
21
1e
1d
24
5e
e 29
27
Description of Research Expertise
60 Psoriatic Arthritis, Axial Spondyloarthritis, Epidemiology, Pharmacoepidemiologye 29
23
11e Landzberg E, Ogdie A, Yarnell C, Harhay MO, Yehya N.: Observational studies of early versus late salvage therapies in critical care exhibit intrinsic selection bias: two meta-analyses. Crit Care 29: 411, Sep 2025.
119 Armstrong AW, Mburu S, Gondo GC, Kornyeyeva E, Frade S, Ogdie A.: Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study. Drugs Real World Outcomes Aug 2025.
201 Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh N, Ogdie A, George MD.: Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA. RMD Open 11: e005839, Aug 2025.
12b Wu A, Zhang A, Guo Y, Liu J, Yang DM, Chada LP, Ogdie A, Reddy SM, Gottlieb AB, Scher JU, Merola JF.: Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis. JAMA Dermatol Aug 2025.
195 Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L.: Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies. RMD Open 11: e005522, Aug 2025.
14a Rice AL, Gillespie S, Sai N, Reddy SM, Merola JF, Haberman RH, Ogdie A, Scher JU.: Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics. J Psoriasis Psoriatic Arthritis Jul 2025.
16a Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO.: Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study. J Rheumatol Jul 2025.
128 Allenzara A, Bush K, Husni ME, Reddy SM, Scher JU, Craig E, Koplin J, Walsh JA, Ogdie A.: Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort. Arthritis Care Res (Hoboken) Mar 2025.
1f3 Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA.: Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials 26: 96, Mar 2025.
2c
7
1d
1f
Selected Publications
17e McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF.: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nat Med Oct 2025.11e Landzberg E, Ogdie A, Yarnell C, Harhay MO, Yehya N.: Observational studies of early versus late salvage therapies in critical care exhibit intrinsic selection bias: two meta-analyses. Crit Care 29: 411, Sep 2025.
119 Armstrong AW, Mburu S, Gondo GC, Kornyeyeva E, Frade S, Ogdie A.: Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study. Drugs Real World Outcomes Aug 2025.
201 Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh N, Ogdie A, George MD.: Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA. RMD Open 11: e005839, Aug 2025.
12b Wu A, Zhang A, Guo Y, Liu J, Yang DM, Chada LP, Ogdie A, Reddy SM, Gottlieb AB, Scher JU, Merola JF.: Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis. JAMA Dermatol Aug 2025.
195 Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L.: Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies. RMD Open 11: e005522, Aug 2025.
14a Rice AL, Gillespie S, Sai N, Reddy SM, Merola JF, Haberman RH, Ogdie A, Scher JU.: Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics. J Psoriasis Psoriatic Arthritis Jul 2025.
16a Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO.: Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study. J Rheumatol Jul 2025.
128 Allenzara A, Bush K, Husni ME, Reddy SM, Scher JU, Craig E, Koplin J, Walsh JA, Ogdie A.: Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort. Arthritis Care Res (Hoboken) Mar 2025.
1f3 Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA.: Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials 26: 96, Mar 2025.
2c